Which test is more cost-effective for colorectal cancer screening? Read the week’s top stories in gastroenterology
Click Here to Manage Email Alerts
A meta-analysis concluded that both annual and biennial fecal immunochemical tests are as effective at detecting colorectal cancer and were more cost-effective than colonoscopy every 10 years. This was the top story in gastroenterology last week.
Other top stories included a report showing that the monoclonal antibody Entyvio (vedolizumab, Takeda) did not compromise the efficacy of anti-tumor necrosis factor treatment in patients with inflammatory bowel disease, and the FDA’s approval of a therapy for ulcerative colitis.
Fecal immunochemical tests more cost-effective than colonoscopy for colorectal cancer screening
Despite some drawback, both annual and biennial fecal immunochemical tests are as effective at detecting colorectal cancer while being more cost-effective than colonoscopy every 10 years, according to results of a meta-analysis. Read more.
Anti-TNF therapy appears effective after first-line Entyvio in IBD
In patients with inflammatory bowel disease, first-line vedolizumab treatment did not appear to compromise the effectiveness of successive anti-TNF treatment in real-world practice, according to findings presented at the American College of Gastroenterology Annual Meeting. Read more.
FDA approves Xeljanz extended - release tablets for ulcerative colitis
The FDA recently approved Xeljanz extended-release 11 mg and 22 mg tablets for the once-daily treatment of adults with moderately to severely active ulcerative colitis, following an inadequate response or intolerance to previous TNF blocker therapy, according to a press release from the manufacturer. Read more.
AI bests nonexpert endoscopists in Barrett’s neoplasia detection
Researchers developed a deep-learning, computer-aided system that detected neoplasia in patients with Barrett’s esophagus at a better rate than nonspecialized endoscopists, according to study results. Read more.
Not dead yet: The role of immunomodulators in IBD
Thiopurine immunomodulators represent a potentially inexpensive and effective method for inflammatory bowel disease maintenance that can be underused as biologics became available, according to a keynote presentation from Advances in Inflammatory Bowel Disease 2019. Read more.